Evaluating the impact of technology in radiotherapy for cancer patients
Partnership Initiative for the Evaluation of Technological Innovation in Radiotherapy
This study is trying to see how technology in radiotherapy affects cancer patients by collecting their health information and experiences during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Drugs / interventions | radiation |
| Locations | 5 sites (London, Ontario and 4 other locations) |
| Trial ID | NCT03378856 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a robust infrastructure for systematically collecting clinical data, patient-reported outcomes, and imaging data from patients undergoing standard-care radiotherapy. It focuses on understanding the effects of radiation and long-term outcomes by creating a prospective cohort of participants who consent to data collection. The study also allows for future randomized controlled trials (RCTs) within the cohort, enabling comparative effectiveness research and exploration of dose-effect relationships. By capturing patient-reported outcomes at baseline and during follow-up, the study seeks to enhance the understanding of radiotherapy's impact on patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who are currently receiving radiotherapy or brachytherapy and can provide informed consent.
Not a fit: Patients who are not receiving radiotherapy or brachytherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of radiotherapy effects, ultimately enhancing patient care and treatment outcomes.
How similar studies have performed: Other studies utilizing similar cohort designs and data collection methods have shown promise in improving patient outcomes and understanding treatment effects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide informed consent * Receiving radiotherapy or brachytherapy Exclusion Criteria: \-
Where this trial is running
London, Ontario and 4 other locations
- London Health Regional Cancer Centre — London, Ontario, Canada (Not_yet_recruiting)
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Not_yet_recruiting)
- Centre de santé et de services sociaux de Laval — Laval, Quebec, Canada (Recruiting)
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada (Recruiting)
- Chuq — Québec, Quebec, Canada (Not_yet_recruiting)
Study contacts
- Study coordinator: Cynthia Ménard, MD, M.Sc
- Email: Cynthia.Menard@umontreal.ca
- Phone: 514-890-8254
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.